Immunoassays for the incretin hormones GIP and GLP-1

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Immunoassays for the incretin hormones GIP and GLP-1. / Deacon, Carolyn F; Holst, Jens J.

In: Best Practice & Research: Clinical Endocrinology & Metabolism, Vol. 23, No. 4, 2009, p. 425-32.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Deacon, CF & Holst, JJ 2009, 'Immunoassays for the incretin hormones GIP and GLP-1', Best Practice & Research: Clinical Endocrinology & Metabolism, vol. 23, no. 4, pp. 425-32. https://doi.org/10.1016/j.beem.2009.03.006

APA

Deacon, C. F., & Holst, J. J. (2009). Immunoassays for the incretin hormones GIP and GLP-1. Best Practice & Research: Clinical Endocrinology & Metabolism, 23(4), 425-32. https://doi.org/10.1016/j.beem.2009.03.006

Vancouver

Deacon CF, Holst JJ. Immunoassays for the incretin hormones GIP and GLP-1. Best Practice & Research: Clinical Endocrinology & Metabolism. 2009;23(4):425-32. https://doi.org/10.1016/j.beem.2009.03.006

Author

Deacon, Carolyn F ; Holst, Jens J. / Immunoassays for the incretin hormones GIP and GLP-1. In: Best Practice & Research: Clinical Endocrinology & Metabolism. 2009 ; Vol. 23, No. 4. pp. 425-32.

Bibtex

@article{e0623420334011df8ed1000ea68e967b,
title = "Immunoassays for the incretin hormones GIP and GLP-1",
abstract = "The measurement of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), using immunologically based assays is made difficult by the fact that the processing of the precursor molecules gives rise to a number of different peptides which cross-react with antisera raised against the two hormones. For GLP-1, the picture is further complicated because of the necessity to differentiate between the intestinal and pancreatic proglucagon products. Finally, once secreted, both incretins are rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) to generate metabolites which have lost their insulinotropic activities. These metabolites are the major circulating forms of the incretins, accounting for 60-80% of total immunoreactive GLP-1 and GIP in the peripheral plasma, while concentrations of the intact forms can be very low and, in some cases, barely detectable. The use of highly specific assays using well-characterised antisera and careful sample handling is therefore required for a reliable determination of incretin hormone concentrations.",
author = "Deacon, {Carolyn F} and Holst, {Jens J}",
note = "Keywords: Antigens, CD26; Cross Reactions; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Proglucagon; Radioimmunoassay",
year = "2009",
doi = "10.1016/j.beem.2009.03.006",
language = "English",
volume = "23",
pages = "425--32",
journal = "Best Practice and Research in Clinical Endocrinology and Metabolism",
issn = "1521-690X",
publisher = "Elsevier",
number = "4",

}

RIS

TY - JOUR

T1 - Immunoassays for the incretin hormones GIP and GLP-1

AU - Deacon, Carolyn F

AU - Holst, Jens J

N1 - Keywords: Antigens, CD26; Cross Reactions; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Proglucagon; Radioimmunoassay

PY - 2009

Y1 - 2009

N2 - The measurement of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), using immunologically based assays is made difficult by the fact that the processing of the precursor molecules gives rise to a number of different peptides which cross-react with antisera raised against the two hormones. For GLP-1, the picture is further complicated because of the necessity to differentiate between the intestinal and pancreatic proglucagon products. Finally, once secreted, both incretins are rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) to generate metabolites which have lost their insulinotropic activities. These metabolites are the major circulating forms of the incretins, accounting for 60-80% of total immunoreactive GLP-1 and GIP in the peripheral plasma, while concentrations of the intact forms can be very low and, in some cases, barely detectable. The use of highly specific assays using well-characterised antisera and careful sample handling is therefore required for a reliable determination of incretin hormone concentrations.

AB - The measurement of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), using immunologically based assays is made difficult by the fact that the processing of the precursor molecules gives rise to a number of different peptides which cross-react with antisera raised against the two hormones. For GLP-1, the picture is further complicated because of the necessity to differentiate between the intestinal and pancreatic proglucagon products. Finally, once secreted, both incretins are rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) to generate metabolites which have lost their insulinotropic activities. These metabolites are the major circulating forms of the incretins, accounting for 60-80% of total immunoreactive GLP-1 and GIP in the peripheral plasma, while concentrations of the intact forms can be very low and, in some cases, barely detectable. The use of highly specific assays using well-characterised antisera and careful sample handling is therefore required for a reliable determination of incretin hormone concentrations.

U2 - 10.1016/j.beem.2009.03.006

DO - 10.1016/j.beem.2009.03.006

M3 - Journal article

C2 - 19748060

VL - 23

SP - 425

EP - 432

JO - Best Practice and Research in Clinical Endocrinology and Metabolism

JF - Best Practice and Research in Clinical Endocrinology and Metabolism

SN - 1521-690X

IS - 4

ER -

ID: 18699416